Boehringer Ingelheim ’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis

Boehringer Ingelheim ’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis

Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news